# A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

> **NCT04192344** · PHASE1 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 276 (estimated)

## Conditions studied

- Neoplasms
- Tenosynovial Giant Cell Tumor

## Interventions

- **DRUG:** ABSK021

## Key facts

- **NCT ID:** NCT04192344
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04192344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04192344, "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04192344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*